Literature DB >> 10413606

Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells.

U M Malyankar1, R Hanson, S M Schwartz, A L Ridall, C M Giachelli.   

Abstract

Vascular smooth muscle cells (SMCs) undergo a dramatic phenotypic transition in response to injury and ex vivo culture that includes enhanced proliferation, migration, matrix deposition, and alterations in gene expression. Osteopontin is a good marker for the injury-induced SMC phenotypic state in vivo and in vitro. To identify transcription factors that might control the regulation of osteopontin expression, we investigated cultured vascular SMCs that express high and low levels of osteopontin. Using nuclear run-on assays, mRNA stability studies, and deletion analysis, we demonstrate that regulation of osteopontin steady-state mRNA levels in SMCs occurs at the transcriptional level. Transient transfection and gel-shift analyses of osteopontin promoter indicated that a region between -123 and +66 was involved in the expression of osteopontin. Supershift EMSAs identified the bHLH-leucine zipper transcription factor upstream stimulatory factor-1 (USF1) as the protein binding to this sequence. Finally, we show that USF1 protein is induced in vivo within 24 h of balloon angioplasty of rat carotids coordinately with osteopontin induction. These data suggest that USF1 governs expression of osteopontin in cultured vascular SMCs and might contribute to initial osteopontin expression observed post carotid injury and in vascular pathologies in vivo. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10413606     DOI: 10.1006/excr.1999.4537

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  8 in total

1.  NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells.

Authors:  M Takemoto; M Kitahara; K Yokote; S Asaumi; A Take; Y Saito; S Mori
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Binding of USF to a non-canonical E-box following stress results in a cell-specific derepression of the lama3 gene.

Authors:  Thierry Virolle; Christelle Coraux; Olivier Ferrigno; Laurence Cailleteau; Jean-Paul Ortonne; Philippe Pognonec; Daniel Aberdam
Journal:  Nucleic Acids Res       Date:  2002-04-15       Impact factor: 16.971

3.  Association analysis of allelic variants of USF1 in coronary atherosclerosis.

Authors:  Kati Kristiansson; Erkki Ilveskoski; Terho Lehtimäki; Leena Peltonen; Markus Perola; Pekka J Karhunen
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-02-14       Impact factor: 8.311

4.  Polyomavirus middle T antigen induces the transcription of osteopontin, a gene important for the migration of transformed cells.

Authors:  Kerry A Whalen; Georg F Weber; Thomas L Benjamin; Brian S Schaffhausen
Journal:  J Virol       Date:  2008-03-12       Impact factor: 5.103

Review 5.  Integration of non-SMAD and SMAD signaling in TGF-beta1-induced plasminogen activator inhibitor type-1 gene expression in vascular smooth muscle cells.

Authors:  Rohan Samarakoon; Paul J Higgins
Journal:  Thromb Haemost       Date:  2008-12       Impact factor: 5.249

6.  Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells.

Authors:  Yoji Takami; Michael B Russell; Chengjiang Gao; Zhiyong Mi; Hongtao Guo; Christopher R Mantyh; Paul C Kuo
Journal:  Surgery       Date:  2007-08       Impact factor: 3.982

Review 7.  Transcriptional regulation of osteopontin and the metastatic phenotype: evidence for a Ras-activated enhancer in the human OPN promoter.

Authors:  David T Denhardt; Devra Mistretta; Ann F Chambers; Shuba Krishna; Joseph F Porter; Srilatha Raghuram; Susan R Rittling
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  USF1 promotes the development of knee osteoarthritis by activating the NF-κB signaling pathway.

Authors:  Xiandong Song; Min Zhu; Hao Li; Bo Liu; Zhaowei Yan; Weican Wang; Hongyi Li; Jiping Sun; Shixing Li
Journal:  Exp Ther Med       Date:  2018-08-14       Impact factor: 2.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.